• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Conversion of the active to latent plasminogen activator inhibitor from human endothelial cells.

作者信息

Levin E G, Santell L

机构信息

Department of Basic and Clinical Research, Scripps Clinic and Research Foundation, La Jolla, CA 92037.

出版信息

Blood. 1987 Oct;70(4):1090-8.

PMID:3498518
Abstract

The plasminogen activator inhibitor from human endothelial cells (PAI-1) exists in two forms in the culture medium: an active form that binds to and inactivates plasminogen activators and a latent form that in its native state has no anti-activator activity. Inhibitor activity associated with the latent form can be generated by treatment with protein denaturants and makes up more than 98% of the total inhibitor activity in conditioned medium. Plasminogen activator inhibitor activity is also found in cell cytosol. This inhibitor activity is stable to SDS-treatment but is not enhanced by it. We investigated the relationship between this active cell-associated inhibitor and the latent PAI-1 found in the conditioned medium. Both intracellular and extracellular inhibitors were immunoprecipitated by a monoclonal antibody produced against the latent inhibitor from HT1080 fibrosarcoma cells and electrophoresis on SDS gels of various acrylamide concentrations demonstrated that both forms had the same Mr. Incubation of cytosol inhibitor at 37 degrees C resulted in a decline in inhibitor activity with a half-life of approximately 4 hours, a rate of decline similar to that of the active PAI-1 in conditioned medium, with less than 10% of the original activity present after eight hours. This decline is accelerated at higher temperatures and is not affected by the presence of a variety of protease inhibitors. Approximately 90% of the activity can be regenerated after SDS treatment suggesting that the cell associated inhibitor, during incubation at 37 degrees C, converts to a form similar to that found in conditioned medium. Despite these similarities, the apparent Stoke's radii of the active intracellular inhibitor and the latent inhibitor in conditioned medium were significantly different with values of 2.77 nm and 2.40 nm for active and latent PAI-1, respectively. Incubation of the active form at 37 degrees C resulted in the shift of the Stoke's radius to that similar to the latent PAI-1 (2.45 nm). Thus, the active and latent PAI-1, while being immunologically similar and of the same apparent Mr, can be differentiated by their behavior on gel permeation columns. This suggests that the intracellular inhibitor is a precursor to the latent form.

摘要

相似文献

1
Conversion of the active to latent plasminogen activator inhibitor from human endothelial cells.
Blood. 1987 Oct;70(4):1090-8.
2
Interaction of tissue-type plasminogen activator and plasminogen activator inhibitor 1 on the surface of endothelial cells.组织型纤溶酶原激活剂与纤溶酶原激活剂抑制剂1在内皮细胞表面的相互作用。
J Biol Chem. 1988 Feb 5;263(4):1960-9.
3
Endothelial cells produce a latent inhibitor of plasminogen activators that can be activated by denaturants.内皮细胞产生一种纤溶酶原激活物的潜在抑制剂,该抑制剂可被变性剂激活。
J Biol Chem. 1985 Sep 25;260(21):11581-7.
4
Association of a plasminogen activator inhibitor (PAI-1) with the growth substratum and membrane of human endothelial cells.纤溶酶原激活物抑制剂-1(PAI-1)与人内皮细胞生长基质及细胞膜的关联。
J Cell Biol. 1987 Dec;105(6 Pt 1):2543-9. doi: 10.1083/jcb.105.6.2543.
5
Quantitation and properties of the active and latent plasminogen activator inhibitors in cultures of human endothelial cells.
Blood. 1986 May;67(5):1309-13.
6
Retinal pigment epithelial cells produce a latent fibrinolytic inhibitor that is antigenically and biochemically related to type 1 plasminogen activator inhibitor produced by vascular endothelial cells.视网膜色素上皮细胞产生一种潜在的纤溶酶抑制物,它在抗原性和生物化学性质上与血管内皮细胞产生的1型纤溶酶原激活物抑制物相关。
Exp Eye Res. 1989 Aug;49(2):195-203. doi: 10.1016/0014-4835(89)90090-0.
7
Purification and characterization of natural and recombinant human plasminogen activator inhibitor-1 (PAI-1).
Eur J Biochem. 1988 Aug 15;175(3):531-40. doi: 10.1111/j.1432-1033.1988.tb14225.x.
8
Bovine plasminogen activator inhibitor 1: specificity determinations and comparison of the active, latent, and guanidine-activated forms.
Biochemistry. 1988 Apr 19;27(8):2911-8. doi: 10.1021/bi00408a037.
9
Bovine endothelial cell plasminogen activator inhibitor. Purification and heat activation.牛内皮细胞纤溶酶原激活物抑制剂。纯化与热激活。
Eur J Biochem. 1988 Sep 1;176(1):81-7. doi: 10.1111/j.1432-1033.1988.tb14253.x.
10
Purification of an active plasminogen activator inhibitor immunologically related to the endothelial type plasminogen activator inhibitor from the conditioned media of a human melanoma cell line.从人黑色素瘤细胞系的条件培养基中纯化一种与内皮型纤溶酶原激活物抑制剂具有免疫相关性的活性纤溶酶原激活物抑制剂。
J Biol Chem. 1986 Nov 5;261(31):14474-81.

引用本文的文献

1
Assays to quantify fibrinolysis: strengths and limitations. Communication from the International Society on Thrombosis and Haemostasis Scientific and Standardization Committee on fibrinolysis.定量纤溶的检测方法:优缺点。国际血栓与止血学会科学和标准化委员会关于纤溶的通讯。
J Thromb Haemost. 2023 Apr;21(4):1043-1054. doi: 10.1016/j.jtha.2023.01.008. Epub 2023 Jan 14.
2
Deep mutational scanning and massively parallel kinetics of plasminogen activator inhibitor-1 functional stability to probe its latency transition.深突变扫描和纤溶酶原激活物抑制剂-1 功能稳定性的大规模并行动力学,以探索其潜伏态转变。
J Biol Chem. 2022 Dec;298(12):102608. doi: 10.1016/j.jbc.2022.102608. Epub 2022 Oct 17.
3
Deep mutational scanning of the plasminogen activator inhibitor-1 functional landscape.
深突变扫描纤溶酶原激活物抑制剂-1 的功能图谱。
Sci Rep. 2021 Sep 22;11(1):18827. doi: 10.1038/s41598-021-97871-7.
4
Hypofibrinolysis in diabetes: a therapeutic target for the reduction of cardiovascular risk.糖尿病中的纤维蛋白溶解功能减退:降低心血管风险的治疗靶点。
Cardiovasc Diabetol. 2017 Mar 9;16(1):34. doi: 10.1186/s12933-017-0515-9.
5
Novel plasma biomarkers associated with liver disease severity in adults with nonalcoholic fatty liver disease.与非酒精性脂肪性肝病成人患者肝病严重程度相关的新型血浆生物标志物。
Hepatology. 2017 Jan;65(1):65-77. doi: 10.1002/hep.28776. Epub 2016 Oct 12.
6
Chemical Antagonists of Plasminogen Activator Inhibitor-1: Mechanisms of Action and Therapeutic Potential in Vascular Disease.纤溶酶原激活物抑制剂-1的化学拮抗剂:作用机制及在血管疾病中的治疗潜力
J Mol Genet Med. 2014 Oct;8(3). doi: 10.4172/1747-0862.1000125.
7
A small molecule PAI-1 functional inhibitor attenuates neointimal hyperplasia and vascular smooth muscle cell survival by promoting PAI-1 cleavage.一种小分子PAI-1功能抑制剂通过促进PAI-1裂解来减轻内膜增生和血管平滑肌细胞存活。
Cell Signal. 2015 May;27(5):923-33. doi: 10.1016/j.cellsig.2015.01.009. Epub 2015 Jan 22.
8
Small Molecule Targeting of PAI-1 Function: A New Therapeutic Approach for Treatment of Vascular Stenosis.靶向纤溶酶原激活物抑制剂-1功能的小分子:治疗血管狭窄的新治疗方法。
J Mol Genet Med. 2013 Jul 8;7(2). doi: 10.4172/1747-0862.1000059.
9
Low Molecular Weight Antagonists of Plasminogen Activator Inhibitor-1: Therapeutic Potential in Cardiovascular Disease.纤溶酶原激活物抑制剂-1的低分子量拮抗剂:在心血管疾病中的治疗潜力
Mol Med Ther. 2012 Aug 5;1(1):101. doi: 10.4172/2324-8769.1000102.
10
Characterization of a small molecule inhibitor of plasminogen activator inhibitor type 1 that accelerates the transition into the latent conformation.纤溶酶原激活物抑制剂 1 小分子抑制剂的特性研究,该抑制剂能加速向潜伏构象的转变。
J Biol Chem. 2013 Jan 11;288(2):873-85. doi: 10.1074/jbc.M112.371732. Epub 2012 Nov 15.